NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences
12 sept. 2024 16h04 HE
|
NurExone Biologic Inc
NurExone Biologic Enhances Visibility in Pharmaceutical Industry with Technological Presentations at Major Global Events
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
06 sept. 2024 16h03 HE
|
NurExone Biologic Inc
NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
28 août 2024 08h34 HE
|
NurExone Biologic Inc
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
23 août 2024 16h03 HE
|
NurExone Biologic Inc
NurExone Biologic to present its innovative ExoPTEN therapy at key September conferences in Boston and New York, showcasing its leadership in regenerative
NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
15 août 2024 16h03 HE
|
NurExone Biologic Inc
NurExone’s reliable production from diverse biological sources allows NurExone to optimize exosome production with consistency and efficiency
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
09 août 2024 16h04 HE
|
NurExone Biologic Inc
NurExone announces promising new data for its ExoPTEN nanodrug, highlighting progress towards commercial-grade manufacturing
NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
01 août 2024 16h04 HE
|
NurExone Biologic Inc
NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
NurExone Announces Further Expansion of ExoPTEN Patent Coverage
29 juil. 2024 16h04 HE
|
NurExone Biologic Inc
NurExone Announces Further Expansion of ExoPTEN Patent Coverage in Israel
Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma
17 juil. 2024 16h14 HE
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
Updates from NurExone: Growth Conference Presentation and Website Relaunch
05 juil. 2024 08h43 HE
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...